Highlights of the 13th International Conference on Malignant Lymphoma by BONNET, Christophe & BOSLY, A.






















































1. Xagrid Summary of Product Characteristics, July 2014 
2. Hong Y et al. Platelets. 2002 
3. Petrides et al. Expert Opin Pharmacother 2004
4. Barosi G, Leukemia. 2007 Feb;21(2):277–80
Non-cytotoxic activity that allows 
long-term clinical use: no known mutagenic, 
clastogenic or leukemogenic properties1-3
If, with first-line HU:
• The patient does not achieve an 
adequate response: if the platelet 
count has not reduced to ≤600 x 
109/l after 3 months of HU (or 
≤400 x 109/l where there is a 
low white blood count or low 
haemoglobin)4 
• The patient is HU-intolerant:  
a range of side effects (particularly 
leukopenia, anaemia, leg ulcers, other 
muco-cutaneous manifestations and 
fever) may become unacceptable.4
Xagrid® is indicated for the reduction of elevated platelet counts in at risk essential 
thrombocythaemia (ET) patients who are intolerant to their current therapy or 
whose elevated platelet counts are not reduced to an acceptable level by their 
current therapy.
Hodgkin’s lymphoma
The most important advances were reported in the 
treatment of Hodgkin’s lymphoma.
Firstly, P. Jonhson (Southampton), presented the results 
of the RATHL study, designed to test whether interim 
18FDG PET-CT scanning could assess early chemo-
therapy response and guide subsequent treatment for 
patients with advanced classical Hodgkin’s lymphoma 
(HL). Patients with newly diagnosed unfavourable 
localised or advanced stage HL were initially treated by 
two cycles of ABVD. After that, a 18FDG PET-CT was 
performed to assess the early metabolic response, using 
the Deauville 5-point scale. Patients with negative 
18FDG-PET (score 1-3) were randomised to receive 
four complementary cycles of AVD with or without 
bleomycin. Patients with positive 18FDG-PET (score 
4-5) were treated with BEACOPP-14 or escBEACOPP. 
This study demonstrated, firstly, that bleomycin can 
be omitted for patients in early metabolic response 
(3-years PFS: 85.5% versus 84.5% and OS: 97% versus 
97.5%, respectively for patients who received ABVD or 
AVD) with, as consequence, less pulmonary toxicity 
and, secondly, that radiotherapy can be omitted for this 
patient population in early metabolic complete remission. 
For patients with early 18FDG-PET positive, no difference 
was observed between BEACOPP-14 and escBEACOPP 
(3-year PFS was 68% and OS 86%). (#008)
Secondly, the EORTC-LYSA-FIL intergroup presented 
the outcome of the early 18FDG-PET-positive patients 
included in the H10 prospective randomised study 
(Figure 1). After two cycles of ABVD, patients with at 
least one unfavourable factor (more than fifty years of 
age, four or more involved nodal areas, ESR superior 
to 50 mm/1h without B symptom or superior to 30 
mm/1h with B symptom, or a bulky mediastinum) 
were randomised between two additional courses of 
ABVD followed by 30 Gy Involved Node Radiotherapy 
(INRT) (standard arm) versus a more intensive chemo-
therapy treatment consisting of two cycles of escBEA-
COPP (escalation arm) also followed by 30 Gy INRT. 
18FDG-PET positive patients without any adverse factor 
(favourable group) randomised in the standard arm 
received one additional cycle of ABVD followed by 30 
GY INRT and those randomised in the experimental 
arm benefited from two cycles of escBEACOPP followed 
by  30 GY INRT. With a median follow-up of 4.5 years, 
the authors demonstrate the negative impact of early 
18FDG-PET positivity on PFS and OS. Moreover, in the 
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group of patients with early-PET remaining positive, 
an escalation treatment with escBEACOPP is associated 
with a five year PFS of 91% versus 77% for patients who 
did not receive escalation. Except for haematological 
toxicities, the escBEACOPP treatment was not more 
toxic. For patients with early 18FDG-PET negativity, 
the final analyses confirmed the conclusions of the 
published interim analysis, i.e. they could not show the 
non-inferiority of the no-RT arm as compared to the 
standard combined modality treatment. (#LBA1)
Thirdly, the impressive results obtained with nivolumab 
(NIVO), a fully human IgG4 monoclonal PD-1 blocking 
antibody that is able to potentiate anti-tumour T-cell 
activity, already presented at the ASH meeting in 
December 2014, were updated and confirmed the very 
interesting potentiality of this drug in heavy pretreated 
Hodgkin’s lymphoma with an overall response rate of 
87%. Side-effects are rare and manageable. Among the 
23 patients with HL included in the study, 20 responded. 
Out of them, ten discontinued NIVO, six (one CR and 
five PR) to undergo SCT, three for disease progression, 
one for toxicity (MDS, thrombocytopenia), and ten 
(seven PR and three CR) continue to respond. (#010)
Finally, brentuximab vedotin is now used in association. 
In first-line, coupled with AVD, it procures a CR rate of 
93% for patients with non-bulky limited stage classical 
Hodgkin’s lymphoma. In relapse, its association with 
bendamustine provides promising results. (# 87 & 90)
Diffuse large B-cell lymphomas
Two presentations focused on the place of radiotherapy 
in the treatment of localised diffuse large B-cell lympho-
mas (DLBCL), a topic that remains the subject of debate.
Firstly, D. Stephens (US), presented an update of the 
worldwidely well-known SWOG S8736 phase III ran-
domised study that was published in the NEJM in 1998 
and had demonstrated, for patients with localised 
disease, the superiority in PFS and OS of a combined 
modality treatment (three cycles of CHOP followed by 
an involved field radiotherapy of 40-55 Gy) over eight 
Figure 1. H10 study from the LYSA-FIL-EORTC Intergroup (#LBA1). 
ABVD: Adriamycin, Bleomycin, Vinblastine, Dacarbazine; FDG PET: Fluoro Desoxy Glucose Positron Emission Tomography; 
IN-RT: Involved Node Radiotherapy; Gy: Grays. BEACOPP: Bleomycin, Etoposide, Adriamycin, Cyclophosphamide, Vincristine, 
Procarbazine, Prednisone.
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cycles of CHOP without radiotherapy. In the first publi-
cation, the median follow-up was 4.4 years. In 2001, 
during the ASH annual meeting, Miller already presented 
an update of this study and reported a higher number 
of relapse in the group of irradiated patients with no 
more advantage of the application of radiotherapy. To 
date, with a median follow-up of 17.7 years, 10- and 
15-year PFS estimates in the combined modality arm 
(54% and 40%) are no different from the chemotherapy 
arm (55% and 41%; p=0.91), with continued relapses 
observed beyond five years in both arms. He concluded 
that extended survival data with over seventeen years 
of follow-up show similar PFS/OS with continuous 
treatment failure without a plateau in both arms. The 
addition of rituximab to the three cycles of CHOP does 
not seem to change the natural history of the disease. 
(#128)
J. Vargo (Pittsburgh) illustrated that, between 1998 and 
2012, the use of consolidation radiotherapy after multi-
agent chemotherapy in DLBCL was decreasing in the 
era of modern chemotherapy despite increased adop-
tion of lower radiotherapy doses and modern radiation 
techniques. A retrospective study on 59,255 patients 
identified in the National Cancer Database was per-
formed. Estimated 5- and 10-year overall survival was 
79% and 59% for all patients, 75% and 55% for patients 
receiving multi-agent chemotherapy alone, and 82% and 
64% for patients receiving combined modality therapy 
(p<0.0001). The author emphasises that abandonment 
of combined modality chemotherapy plus radiotherapy 
in favour of multi-agent chemotherapy alone negatively 
affects survival and should be cautioned but, it is 
important to note that the two groups of patients are 
not well-balanced in terms of prognostic factors and 
that the lymphomas of patients treated by chemotherapy 
alone are more advanced. Moreover, the use of rituximab 
was not generalised. (#129)
Follicular lymphomas
The risk of transformation of follicular lymphoma in 
the cohort of the PRIMA trial (six cycles of R-CHOP21 
+ 2R or eight cycles of R-CVP21 followed by rituximab 
maintenance once every two months for two years) 
was analysed by C. Sarkosy (Lyon). Among the 1,017 
responding and randomised patients, a first recurrence 
was observed in 463 patients. The estimated annual 
transformation rate was 1.5%. Patients with histological 
transformation (HT) had significantly more frequently 
altered ECOG-PS, anaemia, high LDH level, B symp-
toms and high FLIPI score at diagnosis. However, initial 
regimen, quality of response to first-line therapy and 
R-maintenance did not impact the HT incidence. HT 
remains quite a rare event associated with poor outcome. 
The outcome of these patients can be improved by per-
forming autologous stem cells transplantation. (#121)
The Follicular Lymphoma Analysis of Surrogacy (FLASH) 
group conducted a prospectively specified meta-analysis 
to evaluate whether treatment effect on the rate of 
patients who achieve complete remission at 30 months 
(CR30), an earlier endpoint, could accurately predict 
treatment effect on PFS. Thirteen randomised studies 
of first-line treatments in FL were eligible. Individual 
patient data (IPD) for 3,837 patients was accessible. 
Correlation of treatment effects on CR30 and on PFS 
was more marked in patients with more aggressive 
disease (stage IV or high FLIPI score). A minimum of 
10% improvement in CR30 over a control rate of 50% 
predicted significant improvement in PFS. Correlation 
between treatment effect on CR30 and PFS in first-line 
chemo/immunotherapy FL trials was highly consistent 
across trial- and IPD-based surrogacy estimation 
methods and across sensitivity analyses. These data 
validate CR30 as a surrogate endpoint in first-line FL 
and support its use to accelerate drug development in 
this setting. (#122)
The primary results of the prospective phase III ran-
domised GADOLIN study was reported by B. Cheson 
(Washington). This study compared the efficacy of six 
cycles of bendamustine 120mg/m² (days 1 and 2, cycles 
1-6) alone to that of bendamustine 90 mg/m2 (days 1 
and 2, cycles 1-6) in combination with GA 101 1000 
mg (days 1, 8 and 15 of cycle 1 and day 1 of cycles 2-6) 
for up to six 28-day cycles. Patients randomised in this 
latter arm received maintenance with GA 101 in mono-
therapy every two months for two years. With a median 
observation time of 20 months, the patients treated by 
bendamustine enjoyed a median PFS of 14.9 months. 
With 22 months of median follow up, the median PFS 
of patients who received immunochemotherapy was 
not reached [hazard ratio (HR) 0.55, 95% confidence 
interval (CI): 0.4-0.74; p=0.00011]. Patients treated 
by chemotherapy alone developed more grades 3 and 
4 thrombocytopenia and anaemia. On the other hand, 
patients who benefited from immunochemotherapy 
presented more neutropenia and infusion-related reac-
tions. (#123)
Chronic lymphocytic leukaemia
J. Bahlo (Cologne), presented a new pre-treatment prog-
nostic index for CLL patients. After review of data 
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from eight phase III trials from France, Germany, UK, 
USA and Poland, including over 3,400 patients, five 
independent predictors for OS were identified: age 
(cut-off 65 yr), clinical stage (Binet A/Rai 0 versus Binet 
B-C/Rai I-IV), del(17p) and/or TP53 mutation, IGHV 
mutation status (MS) and serum β2-microglobulin 
(B2M) [cut-off 3.5 mg/L]. After applying weighted 
grading of the independent factors based on regression 
parameters, a prognostic index was derived separating 
four different risk groups [low (score 0-1), intermediate 
(score 2-3), high (score 4-6) and very high risk (score 
7-10) (Table 2), with significantly different outcomes. 
This new prognostic model will probably be useful for 
current treatment recommendations. (#054)
P. Thornton (Ireland) reported an update of the phase 
III RESONATETM study that compares ibrutinib (420 mg 
once daily) and ofatumumab for patients suffering 
from relapsed/refractory CLL. One hundred and ninety 
five patients received ibrutinib and 196 were treated by 
ofatumumab. In comparison with ofatumumab, treat-
ment with ibrutinib procures higher ORR (90% versus 
25%) and PFS (one year PFS: 84 versus 18%). More-
over, contrary to what is observed with treatment with 
ofatumumab, the efficacy of ibrutinib is independent 
of adverse baseline prognostic factors such as NOTCH1 
mutations, complex karyotype, unmutated IGHV status, 
and 17p or 11q deletion. Most common grade 3/4 
adverse events observed in the cohort of patients treated 
by ibrutinib were neutropaenia (18%), pneumonia (9%), 
thrombocytopaenia (6%), anaemia (6%), hypertension 
(6%) and atrial fibrillation (7%). (#055)
Mantle cell lymphoma
E. Hoster (Germany) presented a new prognostic model 
for patients suffering from a mantle-cells lymphoma. 
After review of the data of two studies from the Euro-
pean Mantle Cells Network (for young and elderly 
patients), it appears that the prognostic value of the 
combination of Ki67 serum level and MIPI is higher 
than those of the histological data such as blastoid 
cytology or diffuse growth pattern. By a simple combi-
nation of MIPI and Ki-67 index, using the previously 
established 30% cut-off, patients could be stratified into 
four groups with largely diverging PFS (5-year rates: 
67%, 46%, 29% and 16%, p<0.0001) and OS (5-year 
rates: 85%, 72%, 43% and 17%, p<0.0001), independent 
of patient age and treatment strategy (Figure 2). (#058) 
S. Legouil (Nantes) presented the results of the LYMA 
trial. In this study, patients younger than 66 years with 
untreated mantle cell lymphoma received four cycles 
of rituximab, high dose aracytine, cisplatine and dexa-
methasone (R-DHAP) followed, for responding patients, 
by intensification with autologous stem cells transplan-
tation conditioned by BEAM. After that, patients were 
randomised between a watch-and-wait attitude versus 
a 3-year rituximab maintenance with an advantage for 
the patients receiving rituximab (3-year EFS: 88.1% 
versus 73.4%, p=0.0057). The advantage of the main-
tenance on OS is not significant. (#061)
Marginal zone lymphomas
C. Thieblemont (Paris) showed a new prognostic model 
focusing on MALT lymphomas generated from the 
dataset of the International Extra Nodal Study Group. 
The demographic, clinical and biological data of the 
393 patients included in the IELSG-19 study and treated 
by chlorambucil, rituximab or rituximab-chlorambucil 
were collected and their impact on event, PFS and OS 
analysed. After application of a backward selection on 
data that were significant in univariate analysis, age 
Table 1. CLL-IPI (#054). 
Variable Adverse factor Coefficient HR Grading
TP53 (17p) Deleted and/or mutated 1.442 4.2 4
IGHV status Unmutated 0.941 2.6 2
B2M (mg/L) > 3.5 0.665 2.0 2
Clinical stage Binet B/C or Rai I-IV 0.499 1.6 1





-Microglobulin; IGHV: immunoglobulin heavy chain variable region genes.
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>70 years, elevated LDH level and stage >2 remained 
significant in multivariate analysis. A prognostic score 
based on the presence of 0.1 or >1 of these three 
adverse factors was able to distinguish three risk 
groups with different 5-year EFS (72%, 58% and 26%; 
p<0.001), 5-year PFS (78%, 63% and 29%; p<0.001) 
and 5-year OS (99%, 92% and 74%; p<0.001). (#124)
CNS lymphomas
During the plenary session, Dr Ferreri (Milan) presented 
the results from the first randomisation of the Interna-
tional Extra Nodal Study Group (IELSG) 32. Firstly, 
this three arm international, multicentre, randomised 
study evaluated the effect of the addition of rituximab 
(375mg/m² on day -5 and 0) with, (arm C) or without 
(arm B) thiotepa (30 mg/m² on day 4) to the MATRIX 
regimen (methotrexate 3.5 g/m² on day 1 and cytarabine 
2x2 gr/m² on days 2 and 3, arm A) in a cohort of 270 
HIV-negative fit patients younger than 70 years suffering 
from primary CNS lymphoma. After four cycles, respon-
ding patients were further randomised to receive whole 
brain radiotherapy or autologous stem cells transplan-
tation conditioned by BCNU and thiotepa. More grade 
4 haematological toxicities were observed for patients 
receiving thiotepa without any increase of the infec-
tious events. Arm C was significantly more active, with 
a CRR of 49%, an ORR of 87% and a 2-year PFS of 
64%, a rate much better than that obtained with the 
addition of rituximab alone (52%) or without any new 
drug (34%). Second randomisation should be permitted 
to confirm the feasibility to perform high rates of 
successful ASC collection. (#009)
The German Cooperative PCNSL group reported 
preliminary results of the ongoing PRIMAIN study in 
which patients older than 65 years, suffering from 
untreated PCNS lymphoma, are treated by three cycles 
combining rituximab (375 mg/m² on days -6 [only 
cycle 1], 1, 15, and 29), methotrexate (3000 mg/m² on 
days 2, 16, and 30), procarbazine (60 mg/m² from 
days 2 to 11), and lomustine (110 mg/m² on day 2) 
followed by a maintenance phase of six cycles procar-
bazine (100mg/m² from day 1 to 5). In this frail popu-
lation, lomustine appeared too toxic and was removed 
from the regimen. The authors demonstrated an over-
all response rate of 74%, a median PFS and OS of 11.5 
and 22.7 months, respectively.  Fifty four deaths were 
observed with six due to the treatment. (#134)
T-cell lymphomas
N. Schmitz (Hamburg) reported the results of pre-planned 
analysis of the Autologous or Allogenic Transplantation 
in T-cell lymphoma (AATT) randomised phase III study, 
designed for young patients with untreated peripheral 
T-cell lymphomas (PTCL). Patients were randomised 
to benefit, after four cycles of CHOP, from autologous 
or allogenic stem cells transplantation. Fifty eight out 
of the 104 enrolled patients were eligible for this 
interim analysis. Only 62% of patients completed treat-
Figure 2. The Combined MIPI (MIPIc) (#058). MIPI: Mantle-Cells Prognostic Index.
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ment as per protocol. Eleven patients were randomised 
to autoSCT but did not proceed to transplantation 
because of progressive disease or no response (n=8), 
infection (n=1) or change of histology (n=2). Fifteen 
patients (54%) randomised to alloSCT did not receive 
it due to progressive disease (n=10) or lack of a fully 
matched donor (n=5). The causes of death are mentioned 
in Table 2. In this small group of patients, no difference 
in OS was observed between the treatment groups. 
Moreover, over 30% of the patients randomised to 
ASCT or alloSCT did not make it to transplantation, 
mostly because of early lymphoma progression. In this 
situation, a conditional power calculation showed a 
low probability (<10%) that the primary endpoint could 
still be met and the investigators decided to close the 
study prematurely. (#033)
Another study focusing on the place of allogenic stem 
cell transplantation in T-cell lymphomas was presented 
by A. Dodero (Milan). He reported the long-term out-
come (median follow-up of 60 months) of 72 patients 
affected by PTCL who underwent alloSCT at diagnosis 
(n=23) or for chemosensitive relapse (n=49) that have 
been enrolled into two transplantation protocols. Fifteen 
out of the 23 patients transplanted in first-line are alive 
in CR, four (17%) died of progressive disease (PD), three 
of non-relapse mortality (NRM) and one of myocardial 
infarction. In the group of patients transplanted after 
relapse, 31 of 49 (63%) patients are alive, 29 in CR, 
eleven (22%) died of PD, six of NRM and one of a 
second cancer. Patients who were transplanted in first 
CR did not have a significant advantage over patients 
who did after relapse (5-year PFS: 59% versus 43%, 
p=0.44; 5-year OS: 60% versus 58%, p=0.82, respec-
tively). (#032)
Conclusion
In Hodgkin’s lymphoma, the role of early PET is now 
clear for patients with localised or advanced diseases. 
For patients with localised diffuse large B-cell lymphoma, 
long-term follow-up of the SWOG S8736 demonstrates 
the non-superiority of chemoradiotherapy treatment 
over chemotherapy alone. In follicular lymphoma, the 
rituximab maintenance doesn’t decrease the incidence 
of histological transformation. In the near future, the 
rate of CR at 30 months could replace PFS as the 
primary endpoint of clinical trials. The new CLL-IPI 
will probably be useful for treatment recommendations. 
In relapsed or refractory CLL, ibrutinib is associated 
with a better response rate and survival than ofatu-
mumab. In mantle cell lymphoma, the combination 
of Ki67 index and MIPI has a better prognostic value 
than MIPI or Ki67 alone. In this disease, rituximab 
maintenance after autologous transplantation is asso-
ciated with better PFS. In MALT lymphomas, age over 
70, advanced stage and high LDH serum level are now 
recognised as important prognostic markers. For young 
patients suffering from CNS lymphoma, the addition 
of thiotepa and rituximab to cytarabine and metho-
trexate improves RR and PFS. For elderly patients, the 
association of procarbazine, methotrexate and rituxi-
mab is promising. Finally, for patients with untreated 
T-cell lymphoma, allogenic stem cell transplantation is 
probably too toxic and autologous transplantation is 
preferred.
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Table 2. Causes of death of patients included in the AATT trial (#033).
Autologous transplantation Allogenic transplantation
Lymphoma progression 7 5
Salvage treatment 1 1
EBV + PTLD 0 1
Infection 0 4
Graft Versus Host Disease 0 2
EBV: Epstein Barr Virus; PTLD: Post-transplant lymphoproliferative disorder 
